CD19 and mantle cell lymphoma: While many trials are currently enrolling patients, the above data suggest the high efficacy of CD19-targeted CAR-T therapy for relapsed or refractory MCL, further underpinning the importance of integrating novel agents, cellular therapies, and transplantation.